Italia markets closed

Dow Jones
38.771,57
+182,41(+0,47%)
Nasdaq
17.901,91
+213,03(+1,20%)
Nikkei 225
38.102,44
-712,12(-1,83%)
EUR/USD
1,0740
+0,0031(+0,29%)
Bitcoin EUR
62.340,81
+339,68(+0,55%)
CMC Crypto 200
1.401,86
+13,70(+0,99%)

NBIX Nov 2024 170.000 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

5,30

0,00

(0,00%)

In data: 11:17AM EDT. Mercato aperto.

GlobeNewswire
Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat